Coltac Therapeutics
Fast-tracking the future of Molecular Glues
- Employees
- 1–10
- Business Model
- B2B
- Website
- coltactx.com
- Last Round
- SeedJan 2025
- Rounds
- 1
About
Coltac Therapeutics discovers next-generation molecular glues using BOND+, a platform that combines advanced in-silico screening with patented bacteria-based high-throughput screening. The system uses synthetic ubiquitylation machinery and bacterial growth as a positive signal to identify compounds that enhance target ubiquitylation. Coltac applies the platform to unique ligases and high-value targets, seeking faster and more selective drug discovery for oncology and other therapeutic areas.
Summary
Coltac Therapeutics is a Biotech company. Its most recent funding was a Seed round in Jan 2025. Investors include aMoon and Israel Biotech Fund.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jan 2025
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/coltac-therapeutics"><img src="https://indexed.vc/api/badge/company/coltac-therapeutics" alt="Coltac Therapeutics on Indexed.vc" width="260" height="76" /></a>